source
- Scribe Therapeutics targets $96 million IPO to fund PCSK9 gene-silencing programScribe Therapeutics, a Bay Area biotech focused on genetic medicines, filed with the SEC outlining plans for an initial public offering on Nasdaq. The company aims to sell 7.1 million shares at $1…
- UK regulator reports rise in drug approvals and new AI healthcare regulationsThe UK's Medicines and Healthcare products Regulatory Agency (MHRA) released its 2025-2026 annual report to Parliament. The agency highlighted that it approved more new medicines in the past year…